On March 22, 2013, IP Osgoode and the Canadian Intellectual Property Office (CIPO) co-hosted a conference examining the role of student researchers in commercializing intellectual
As part of Osgoode’s Intellectual Property Law Intensive Program, I had the opportunity to spend ten weeks at Teva Canada working with in-house counsel. Teva Canada is one
The Canadian pharmaceutical industry is entering a new era as Subsequent Entry Biologic (SEB) litigation begins to emerge in the Canadian pharmaceutical landscape. Biologic drugs
On November 8, 2012 the Supreme Court of Canada (SCC) released its eagerly anticipated decision in the “Viagra Appeal”. In a unanimous decision written by
This Wednesday, April 18, Pfizer will defend the patent protecting the little blue pill that has changed the lives of men and women around the
The Canadian government and European Union (EU) are currently negotiating a Comprehensive Economic and Trade Agreement (CETA). A key issue has been ensuring that Canadian
